CERS — Cerus Corporation

Summary of Cerus Corporation Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Product Revenue: $53.7 million, a 24% increase year-over-year.
• Total Revenue: Increased by 23% compared to Q1 2025.
• Gross Margin: 52%, down from 58.8% in Q1 2025, attributed to inflationary pressures and other headwinds.
• Operating Expenses: Decreased by 7% year-over-year, with SG&A expenses stable.
• GAAP Net Loss: $1.6 million, showing year-over-year improvement.
• Non-GAAP Adjusted EBITDA: $4 million, marking the eighth consecutive quarter of positive adjusted EBITDA.
• Cash and Equivalents: $80.4 million at the end of Q1, down from $82.9 million at the end of 2025.

2. Strategic Updates and Business Highlights

• Core Priorities: Focus on sustainable double-digit growth, advancing innovation, and strengthening financial foundation.
• Platelet Franchise: Continued strength in the U.S. platelet business, with North America accounting for nearly 70% of product revenue.
• International Growth: Strong performance in EMEA, particularly in France and Belgium, bolstered by a multiyear contract with the French Blood Establishment.
• New Agreements: Early traction from the group purchasing agreement with Blood Centers of America, enhancing market penetration.
• Innovation: Successful rollout of the next-generation INT-200 illuminator and plans for U.S. PMA submission for INT-100 this quarter.

3. Forward Guidance and Outlook

• 2026 Product Revenue Guidance: Raised to $227 million to $231 million, reflecting a 10% to 12% growth from 2025.
• IFC Revenue Guidance: Increased to $22 million to $24 million, representing approximately 30% to 40% growth.
• Long-term Growth: Confidence in expanding access to safe blood and achieving GAAP profitability in the future.

4. Challenges and Points of Concern

• Gross Margin Pressures: Expected to remain in the low 50s due to ongoing inflationary pressures, tariffs, and foreign currency impacts.
• Logistical Issues: Ongoing conflict in the Middle East may affect shipment timing, although management believes potential disruptions can be mitigated.
• Market Penetration: Despite strong growth, the company remains a single-digit market share player in the U.S. IFC market, indicating room for improvement.

5. Notable Q&A Insights

• Market Outlook: Management expressed optimism about continued growth in both U.S. and international platelet markets, driven by the BCA agreement.
• Regulatory Milestones: Anticipated CE Mark approval for red blood cells in the first half of 2027, with key milestones expected in Q4 2026.
• China Market: Ongoing efforts to pursue regulatory approval for platelets in China, with potential revenue generation expected later in the decade.
• Transition to Kit Sales: The shift from finished therapeutic sales to kit sales is ongoing, which may introduce variability in revenue recognition.

Overall, Cerus Corporation reported strong financial performance in Q1 2026, with significant growth in product revenue and positive adjusted EBITDA. Strategic initiatives are in place to further enhance market penetration and innovation, although challenges related to gross margins and geopolitical factors remain.